Journal Guide

Drug and Alcohol Review is an international meeting ground for the views, expertise and experience of all those involved in studying alcohol, tobacco and drug problems. Contributors to the Journal examine and report on alcohol and drug use from a wide range of clinical, biomedical, epidemiological, psychological and sociological perspectives. Drug and Alcohol Review particularly encourages the submission of papers which have a harm reduction perspective. However, all philosophies will find a place in the Journal: the principal criterion for publication of papers is their quality.

Drug and Chemical Toxicology publishes full-length research papers, review articles and short communications that encompass a broad spectrum of toxicological data surrounding risk assessment and harmful exposure. Manuscripts are considered according to their relevance to the journal.

For nearly 50 years, DTB has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB was started in 1962. From the outset, it has provided healthcare professionals with independent, clear, reliable information and advice to help ensure patients get the best care. DTB conclusions represent a synthesis of the best available medical evidence with opinions from a wide range of commentators. Published monthly by BMJ, DTB is wholly independent of industry, Government and regulatory authorities and does not carry any display advertising or accept any form of commercial sponsorship.DTB provides articles based on a synthesis of evidence with opinions from a wide range of specialist and generalist commentators, typically over 40 individuals and organisations for each article. Over the years, DTB has initiated successful campaigns for the removal or restriction of medicines that it could not recommend, prompted withdrawal of excessive promotional claims and exposed fundamental weaknesses in certain prescribing practice.Surveys of our readership have consistently shown that readers find DTB authoritative and influential in relation to their decisions, recommendations or advice on treatments. These are just a few of the examples of why DTB is regarded as an indispensable part of evidence-based clinical practice and has been described as both essential reading for practising doctors and as a key information source by the House of Commons Health Select Committee in the UK.

Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For over 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original clinical research authored by leading international clinicians and researchers to support clinical decision-making.   

Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.

As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).

For 30 years Drugs & Aging has been delivering essential information on the most important aspects of drug therapy to researchers and healthcare professionals involved in the care of older patients.

Through a program of reviews and original research articles, the journal addresses major issues relating to drug therapy in older adults, including the management of specific diseases or disorders, particularly those associated with aging, age-related physiological changes impacting drug therapy, and issues related to drug utilization and prescribing.

As a hybrid journal, Drugs & Aging does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Drugs & Aging offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).

Drugs & Therapy Perspectives provides concise, authoritative review articles to aid drug formulary and prescribing decisions. It is a digest of the latest drug knowledge covering the most important aspects of clinical therapeutics, including:Questions and answers on the clinical use of drugs.Comparisons of the features of various drugs, using differential feature tables.Current thinking on disease management.Step-by-step clinical decision-making, illustrated with patient care algorithms.First reports of serious adverse drug reactions.Clinically useful pharmacodynamics and pharmacokinetics.Developments in pharmacoeconomics and other research that have a bearing on clinical practice.All material is prepared by Adis editors and medical writers, unless otherwise noted. The preparation of material is not supported by any external funding. All review articles are subject to peer review by members of the journal's international editorial board and/or other experts.

Drugs - Real World Outcomes targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Drugs - Real World Outcomes has a broad scope, encompassing studies investigating drug utilisation, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness and economic analyses.

Drugs and Alcohol Today journal is committed to bringing together scientific research as well as practitioner and policy reports on the social, economic, and political aspects of alcohol and other drugs.

Drugs in R&D is an international, peer reviewed, open access, online only journal, which provides timely information on emerging drug classes and new treatments for specific disorders in an ‘open access’ format for all to review. Original research and reviews from all phases of clinical development are included, with a strong link to clinical practice. Healthcare decision makers are thus provided with clinically applicable knowledge about the likely place in therapy of a drug.Journal issues comprise:·        Original research on new drugs, including clinical trials:·        New research on established drugs.·        R&D Insight reports:Short communications and letters to the editor are welcomed and will be considered for publication. Reviews may also be considered. All manuscripts are subject to peer review by international experts.